Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Dokumenty

MAB1620

Sigma-Aldrich

Anti-Cytokeratin 5 Antibody, 6, clone D5/16B4

clone D5/16B4, Chemicon®, from mouse

Synonim(y):

58 kDa cytokeratin, Cytokeratin-5, CK-5, Keratin-5, K5, Type-II keratin Kb5

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

pochodzenie biologiczne

mouse

Poziom jakości

forma przeciwciała

purified immunoglobulin

klon

D5/16B4, monoclonal

reaktywność gatunkowa

rat, mouse, human

producent / nazwa handlowa

Chemicon®

metody

immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable

izotyp

IgG1

numer dostępu NCBI

numer dostępu UniProt

Warunki transportu

wet ice

docelowa modyfikacja potranslacyjna

unmodified

informacje o genach

human ... KRT5(3852)

Opis ogólny

The cytokeratins are a family of intermediate filaments found in almost all epithelial cells. They are divided into four subclasses depending on their patterns of reactivity and electrophoretic characteristics and are also arranged I a numbered series of 20 or more acoring to molecular weight and isoelectric point (Quinlan et al. 1985). Types 5 and 6 of cytokeratin (CK5/6) are in high frequency in mesothelial cells, as opposed to cells of adenocarcinoma. CK5/6 has been shown to be a reliable marker for mesothelioma and squamous cell carcinoma of the lung and Bowen′s disease. It does not react with pulmonary adenocarcinoma.

Specyficzność

Expected to cross-react with mouse and rat.
Reacts with human cytokeratin 5 on immunoblots of cytoskeletal preparations of epidermis and non-cytokeratinizing epithelium (Abstract: European Symposium of the Biology of the Cytoskeleton, Helsinki, 18-21, 6, 89, 1989) and on tissue sections. Shows reactivity with cytokeratin 6 and weak reactivity with cytokeratin 4 on immunoblots. No cross-reactivity with cytokeratins 1, 7, 8, 10, 13, 14, 18 or 19. MAB1620 recognizes basal cells and a part of the stratum spinosum in the normal pavement epithelium. The antibody may be useful for distinction of low differentiated pavement epithelium carcinoma and adenocarcinoma. The antibody works on formalin fixed tissues.

Immunogen

Purified cytokeratin 5 (Exp. Cell Res. (1986) 162:114; J. Invest. Dermatology (1987) 88:191).

Zastosowanie

Anti-Cytokeratin 5 Antibody, 6, clone D5/16B4 is an antibody against Cytokeratin 5 for use in IF, IH(P) & WB.
Immunohistochemistry (frozen or paraffin sections):
A 1:50-1:100 dilution from a previous lot was used for paraffin, high-temperature antigen retrieval required (Pressure cooker, Citrate/EDTA buffer pH 6.0, 4 minutes at full pressure).

Immunofluorescence:
A previous lot of this antibody was used in Immunofluorescence.

Western blot:
Recognizes a 58kDa and 56kDa band corresponding to cytokeratin 5 and 6.

Optimal working dilutions must be determined by end user.
Research Category
Cell Structure
Research Sub Category
Cytoskeleton

Jakość

Routinely evaluated by Western Blot on A431 lysates.

Western Blot Analysis:
1:500 dilution of this lot detected cytokeratin 5/6 on 10 ug of A431 lysates.

Opis wartości docelowych

Cytokeratin 4 (59 kDa), Cytokeratin 5 (58 kDa) and Cytokeratin 6 (56 kDa).

Postać fizyczna

Format: Purified
Protein A purified
Purified mouse monoclonal IgG1 in buffer containing 0.02 M Phosphate buffer, 0.25 M NaCl, pH 7.6 with 0.1% sodium azide.

Przechowywanie i stabilność

Stable for 6 months at 2-8°C in undiluted aliquots from date of receipt.

Komentarz do analizy

Control
A431 cell lysate, human bladder tumor tissue.

Inne uwagi

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Informacje prawne

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Oświadczenie o zrzeczeniu się odpowiedzialności

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
This page may contain text that has been machine translated.

Kod klasy składowania

10 - Combustible liquids

Klasa zagrożenia wodnego (WGK)

WGK 2


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Katarzyna Sosińska-Mielcarek et al.
Breast (Edinburgh, Scotland), 22(6), 1178-1183 (2013-09-26)
There are no clinically useful biomarkers predictive of brain metastases (BM) in breast cancer. In this study, we investigated the correlation between expression of selected proteins in the primary tumor and the risk of BM in patients with metastatic breast
Suzete de Silva Rudland et al.
The American journal of pathology, 179(2), 1061-1072 (2011-08-02)
Two subgroups of invasive breast carcinomas have been identified with a poor prognosis in different patient cohorts: the basal-like category and the subgroup containing proteins capable of inducing metastasis in experimental rodents, the metastasis-inducing proteins (MIPs). Here we identify by
D Allende et al.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 26(3), 314-318 (2012-09-27)
Patients with Barrett's esophagus are at risk for dysplasia and esophageal adenocarcinoma. Although surgery was the mainstay treatment for Barrett's dysplasia and cancer, patients with high-grade dysplasia and early cancers now have several nonsurgical treatment options. Most of the endoscopic
Variation and frequency of cytokeratin polypeptide patterns in human squamous non-keratinizing epithelium.
Wild, G A and Mischke, D
Experimental Cell Research, 162, 114-126 (1986)
Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients.
Winczura, P; Sosinska-Mielcarek, K; Duchnowska, R; Badzio, A; Lakomy, J; Majewska et al.
Pathology Oncology Research null

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej